Correlative Analysis Between Magnetic Resonance Spectroscopy (MRS) and Essential Clinicobiological Data in Glioblatoma Multiforme (GBM)

NANot yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2029

Conditions
GlioblastomaMRI SpectroscopyTumor MicroenvironmentBiomarkers / Blood
Interventions
DEVICE

MRS study

"Thirty patients newly diagnosed with GBM will be included in this study. The study will be conducted without any major modification of the standard management of GBM.~The MRS study will be performed at the time of the initial MRI examination (morphological MRI sequences performed on 3T Philipps). The MRS will be performed on the most agressive part of the tumor : monovoxel PRESS MRS sequence with 3 echo times : 35, 144 and 288 ms. Spectra processing with Philipps software returns relative quantifications \> 7 ratios (choline/creatin, Glucose/creatin, glutamine/creatin, N-Acetyl aspartate/creatin, myoinositol/creatin, phsopholipids/creatin, lactate/creatin, acetate/creatin). With this experimental design, the additional time required for MRS acquisition is 10 min /patient."

BIOLOGICAL

blood samples

Routine basic clinical and biological analyses will be collected during the project. In addition, 2 blood samples (5 mL each time) will be obtained at the time of inclusion (pre-therapeutic) and one month after completion of the initial therapeutic cycle (surgery + radiochemotherapy). The plasma samples will be used to measure fibrinogen, lactate and choline concentrations. In addition, a metabolomic study of plasma will be performed w

Trial Locations (1)

80054

CHU Amiens, Amiens

All Listed Sponsors
lead

Centre Hospitalier Universitaire, Amiens

OTHER

NCT07211841 - Correlative Analysis Between Magnetic Resonance Spectroscopy (MRS) and Essential Clinicobiological Data in Glioblatoma Multiforme (GBM) | Biotech Hunter | Biotech Hunter